Contact us for more information at firstname.lastname@example.org or 01494 781510.
Coglapix® provides cross-serotype protection against Actinobacillus pleuropneumoniae (A.p). This effective protection, without post vaccination reactions, gives each pig the ability to breathe easily and therefore gain without pain.
Porcine pleuropneumonia caused by Actinobacillus pleuropneumoniae (A.p.) is a highly contagious respiratory disease, characterised by rapid onset, short course, high morbidity and mortality. The disease spreads worldwide and there are various levels of perception, diagnostic and monitoring measures available in addition to preventive programs.
Pleuropneumonia mostly affects growing and finishing pigs, but can also be present in nursery pigs and gilts. It can appear as a singular disease, or more frequently as an important part of the porcine respiratory disease complex (PRDC). Correct diagnostics and implementation of appropriate monitoring methods are important factors for the success of preventive measures applied to the control of the disease.
Mycoplasma hyopneumoniae, associated with enzootic pneumonia, plays a major role in the porcine respiratory disease complex (PRDC) and can cause huge economic losses. A 17% decrease in daily weight gain and a 14% decrease in feed efficiency has been reported in herds with enzootic pneumonia.
Mycoplasma hyopneumoniae is unable to penetrate and live within host cells but does colonise the mucosal surface of the ciliated epithelium of the respiratory system. In addition to the detrimental effect on the cilia, Mycoplasma hyopneumoniae infection attracts lymphocytes and macrophages into the lungs resulting in pneumonia. Protection against the infection requires complex activation of the host immune system.
After a single injection, Hyogen® provides effective protection against Mycoplasma hyopneumoniae due to the potent stimulation of the immune system by the antigen originated from Ceva Mycoplasma hyopneumoniae strain BA 2940-99 along with the adjuvant, Imuvant™.
- A single vaccination at 21 days of age provides early and long-lasting protection for up to 26 weeks
- Contains the highly potent Ceva proprietary strain BA 2940-99
- Imuvant™, a unique Ceva adjuvant
Ceva Lung Program
The Ceva Lung Program offers the methodology and guidelines on how to correctly evaluate the presence, incidence, circulation patterns and impact of Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae and Aujeszky’s disease virus infections using serological investigation and adapted lung scoring of slaughter pigs.
The Ceva Lung Program Scoring methodology is designed to assist in identifying the correct diagnosis of respiratory disease through the evaluation of lungs at slaughter. It also enables the discovery of subclinical infections that were not noted during the growing period